These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12386962)

  • 1. [Mycoses].
    Yamazumi T; Furuta I
    Rinsho Byori; 2002 Sep; 50(9):853-9. PubMed ID: 12386962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
    Cuenca-Estrella M; Gomez-Lopez A; Gutierrez MO; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1062-5. PubMed ID: 18195057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal susceptibility testing: progress and future developments.
    Pfaller MA
    Braz J Infect Dis; 2000 Apr; 4(2):55-60. PubMed ID: 11012296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
    Cantón E; Espinel-Ingroff A; Pemán J
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):107-19. PubMed ID: 19622060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on clinical antifungal susceptibility testing for Candida species.
    Lewis RE; Klepser ME; Pfaller MA
    Pharmacotherapy; 1998; 18(3):509-15. PubMed ID: 9620102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of in vitro antifungal susceptibility testing.
    Espinel-Ingroff A
    Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues in antifungal susceptibility testing.
    Johnson EM
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i13-8. PubMed ID: 18063599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
    Marangon FB; Miller D; Giaconi JA; Alfonso EC
    Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance.
    Espinel-Ingroff A; Warnock DW; Vazquez JA; Arthington-Skaggs BA
    Med Mycol; 2000; 38 Suppl 1():293-304. PubMed ID: 11204157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility testing in fungi: a global perspective on a variety of methods.
    Lass-Flörl C; Perkhofer S; Mayr A
    Mycoses; 2010 Jan; 53(1):1-11. PubMed ID: 20078786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.
    Cuenca-Estrella M; Rodriguez-Tudela JL
    Expert Rev Anti Infect Ther; 2010 Mar; 8(3):267-76. PubMed ID: 20192681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis.
    Qiu WY; Yao YF; Zhu YF; Zhang YM; Zhou P; Jin YQ; Zhang B
    Curr Eye Res; 2005 Dec; 30(12):1113-20. PubMed ID: 16354625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An update on antifungal susceptibility testing].
    Tapia P CV
    Rev Chilena Infectol; 2009 Apr; 26(2):144-50. PubMed ID: 19621145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
    Morace G; Polonelli L;
    Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biofilm production and antifungal susceptibility patterns of Candida species].
    Yücesoy M; Karaman M
    Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).
    Cuenca-Estrella M; Arendrup MC; Chryssanthou E; Dannaoui E; Lass-Florl C; Sandven P; Velegraki A; Rodriguez-Tudela JL;
    Clin Microbiol Infect; 2007 Oct; 13(10):1018-22. PubMed ID: 17697001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of resistance to antifungals.
    Rodriguez-Tudela JL; Alcazar-Fuoli L; Cuesta I; Alastruey-Izquierdo A; Monzon A; Mellado E; Cuenca-Estrella M
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S111-3. PubMed ID: 19013333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.